Lindsey R Mitrani1, Jeffeny De Los Santos2, Elissa Driggin1, Rebecca Kogan2, Stephen Helmke2, Jeff Goldsmith3, Angelo B Biviano4, Mathew S Maurer2. 1. Department of Internal Medicine, New York Presbyterian/Columbia University Medical Center, New York City, NY, USA. 2. Department of Cardiology, Columbia University, New York City, NY, USA. 3. Mailman School of Public Health, Columbia University, New York City, NY, USA. 4. Department of Cardiac Electrophysiology, Columbia University, New York City, NY, USA.
Abstract
BACKGROUND: Atrial fibrillation (AF) is common in patients with transthyretin cardiac amyloidosis (ATTR-CA). The optimal strategy to prevent strokes in patients with ATTR-CA and AF is unknown. OBJECTIVES: To compare outcomes in patients with ATTR-CA and AF treated with warfarin versus novel oral anticoagulants (NOACs). METHODS: This study was a retrospective analysis of patients with ATTR-CA stratified by presence or absence of AF and anticoagulation therapy. The primary outcome included a time to event analysis for the combined outcomes of stroke, transient ischaemic attack (TIA), major bleed, or death. RESULTS: Of 290 patients, 217 patients (74.8%) had AF. Of those with AF (n = 217), 78 (35.9%) patients received warfarin compared with 116 (53.5%) patients who received NOACs. There were 17 thrombotic events, all in those diagnosed with AF compared with none in the patients without AF (p = .01). Over a mean follow-up of 2.4 years (range 0.1-12) there was no difference in primary outcome between those with AF treated with warfarin compared with NOACs (p = .35). CONCLUSION: Patient with ATTR-CA and AF are at increased risk for stroke compared to patients with ATTR-CA and without AF. Thrombotic events and major bleeds did not differ between those who received warfarin and NOACs.
BACKGROUND: Atrial fibrillation (AF) is common in patients with transthyretin cardiac amyloidosis (ATTR-CA). The optimal strategy to prevent strokes in patients with ATTR-CA and AF is unknown. OBJECTIVES: To compare outcomes in patients with ATTR-CA and AF treated with warfarin versus novel oral anticoagulants (NOACs). METHODS: This study was a retrospective analysis of patients with ATTR-CA stratified by presence or absence of AF and anticoagulation therapy. The primary outcome included a time to event analysis for the combined outcomes of stroke, transient ischaemic attack (TIA), major bleed, or death. RESULTS: Of 290 patients, 217 patients (74.8%) had AF. Of those with AF (n = 217), 78 (35.9%) patients received warfarin compared with 116 (53.5%) patients who received NOACs. There were 17 thrombotic events, all in those diagnosed with AF compared with none in the patients without AF (p = .01). Over a mean follow-up of 2.4 years (range 0.1-12) there was no difference in primary outcome between those with AF treated with warfarin compared with NOACs (p = .35). CONCLUSION: Patient with ATTR-CA and AF are at increased risk for stroke compared to patients with ATTR-CA and without AF. Thrombotic events and major bleeds did not differ between those who received warfarin and NOACs.
Authors: Blaithnead Murtagh; Stephen C Hammill; Morie A Gertz; Robert A Kyle; A Jamil Tajik; Martha Grogan Journal: Am J Cardiol Date: 2005-02-15 Impact factor: 2.778
Authors: Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer Journal: J Am Coll Cardiol Date: 2019-06-11 Impact factor: 24.094
Authors: Christoph Röcken; Brigitte Peters; Gina Juenemann; Wolfgang Saeger; Helmut U Klein; Christof Huth; Albert Roessner; Andreas Goette Journal: Circulation Date: 2002-10-15 Impact factor: 29.690
Authors: DaLi Feng; Imran S Syed; Matthew Martinez; Jae K Oh; Allan S Jaffe; Martha Grogan; William D Edwards; Morie A Gertz; Kyle W Klarich Journal: Circulation Date: 2009-05-04 Impact factor: 29.690
Authors: Julian D Gillmore; Mathew S Maurer; Rodney H Falk; Giampaolo Merlini; Thibaud Damy; Angela Dispenzieri; Ashutosh D Wechalekar; John L Berk; Candida C Quarta; Martha Grogan; Helen J Lachmann; Sabahat Bokhari; Adam Castano; Sharmila Dorbala; Geoff B Johnson; Andor W J M Glaudemans; Tamer Rezk; Marianna Fontana; Giovanni Palladini; Paolo Milani; Pierluigi L Guidalotti; Katarina Flatman; Thirusha Lane; Frederick W Vonberg; Carol J Whelan; James C Moon; Frederick L Ruberg; Edward J Miller; David F Hutt; Bouke P Hazenberg; Claudio Rapezzi; Philip N Hawkins Journal: Circulation Date: 2016-04-22 Impact factor: 29.690
Authors: David D McManus; Grace Hsu; Sue Hee Sung; Jane S Saczynski; David H Smith; David J Magid; Jerry H Gurwitz; Robert J Goldberg; Alan S Go Journal: J Am Heart Assoc Date: 2013-02-01 Impact factor: 5.501
Authors: Eve Cariou; Kevin Sanchis; Khailène Rguez; Virginie Blanchard; Stephanie Cazalbou; Pauline Fournier; Antoine Huart; Murielle Roussel; Pascal Cintas; Michel Galinier; Didier Carrié; Philippe Maury; Yoan Lavie-Badie; Olivier Lairez Journal: Front Cardiovasc Med Date: 2021-11-30
Authors: Erica Irene Uneus; Christer Wilhelmsson; David Bäckström; Intissar Anan; Jonas Wixner; Björn Pilebro; Katrine Riklund; Mattias Ögren; Margareta Ögreen; Jan Axelsson; Ole B Suhr; Torbjörn Sundström Journal: Front Neurol Date: 2022-03-04 Impact factor: 4.003